Dengue fever is a major tropical infectious disease that affects 50-100 million people each year. Its complications, namely dengue haemorrhagic fever and dengue shock syndrome, disproportionately afflict children and young adults. The primary goal of several vaccines now in development is to elicit protective neutralizing antibody responses; however, the exact definition of such responses remain unclear. Here, we review briefly the historical aspects of dengue vaccine development and current candidate dengue vaccines, and discuss various laboratory assays for gauging the neutralizing antibody responses to infection or vaccination, or both. We conclude that modification of current neutralization assays is required to improve the correlation between neutralization end point determinations and protection against secondary heterotypic dengue infections.
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Dengue virus (DENV) infection is endemic in over 100 countries, affecting between 50-100 million people each year in tropical and subtropical regions of the globe. Efforts to control the spread of DENV by limiting the spread of its vector, the Aedes agypti mosquito, have been largely unsuccessful because of increased urbanization and global travel. Primary infection with any of four circulating dengue serotypes (DENV-1, -2, -3 and -4) provides lifelong immunity against the infecting serotype. Secondary heterotypic infection can still occur, however, and might be complicated by dengue haemorrhagic fever (DHF) or dengue shock syndrome. Clinically unmanaged DHF or dengue shock syndrome is often fatal. Therefore, a safe and effective vaccine against DENV infection is urgently needed.
To develop safe, effective and durable human viral vaccines, two conditions are particularly desirable: first, the existence of an animal model that faithfully reproduces signs and pathology of the particular human disease upon virus challenge; and second, an immune response laboratory measurement that can reliably and unambiguously predict protective immunity. Among medically important flaviviruses for which vaccines have been sought, such as yellow fever, West Nile and dengue, dengue falls short of meeting these two goals. Monkeys develop viraemia upon challenge but not typical signs of dengue. Fever, if present, is typically low grade, rash is often absent, haematological changes are inconstant, and complicated forms of human dengue infection that are characterized by microvascular leakage syndromes of haemorrhage and shock do not occur. However, it is the measurement and prediction of protective immunity that is most challenging. As with other flaviviruses, neutralizing antibodies are generally believed to be necessary and probably sufficient to prevent dengue infection, and their stimulation by candidate dengue vaccines is a requisite for vaccine efficacy [1, 2] . However, the most reliable way to measure protective neutralizing activity has not yet been established.
Virulent DENV challenge studies in human vaccinees are no longer feasible, and the correlative results from seroepidemiological studies in which multiple serotypes cocirculate among individuals are difficult to interpret. To further complicate matters, some naturally-infected individuals with relatively high titre serotype-specific neutralizing antibody can remain susceptible to subsequent infection [3] . This raises the obvious question of whether similarly high neutralizing antibody titres stimulated by candidate dengue vaccines will protect against natural infection. Monkeys that develop high titre neutralizing antibodies to live-attenuated dengue vaccines might still be viraemic after homologous DENV challenge, whereas others with relatively low neutralizing titres might be protected, so that there is Introduction often no clear correlation between neutralizing antibody titres measured by a conventional plaque reduction neutralization test (PRNT) and protection defined by abrogation of viraemia [4] . Interpretation of such results is further confounded by the generally agreed upon need to develop a tetravalent dengue vaccine formulation, one that simultaneously generates protective neutralizing antibodies against all four dengue serotypes, lest a vaccinated individual might be susceptible to enhanced disease upon subsequent natural infection with wildtype virus. Importantly, no standard assay exists to define and measure such hypothetically undesirable dengue antibodies, that is, those that might paradoxically enhance DENV replication and thereby cause more severe disease [5] .
PRNT conventionally performed in epithelial cell lines of animal origin have neither been formally standardized among laboratories, nor have PRNT titres that correlate with protection been rigorously defined. A 50% PRNT (PRNT 50 ) end point measurement has been recommended [6] , but not strictly adhered to in candidate dengue vaccine trials. Individuals with heterotypic neutralizing antibodies acquired by natural infection might still be susceptible to subsequent infection [3] ; the same is true in denguevaccinated monkeys subsequently challenged with DENV [4, 7, 8] . Further contributing to this deficiency has been the arbitrary choice of DENV strains used in the performance of neutralization tests. In some instances, the vaccine virus strain itself or its partially attenuated parent (that is, 'near-wild-type') has been used to measure neutralizing antibodies [4] . Virus neutralization assays generally seek to measure protective antibodies. When performed in conventional cell types, such assays measure antibody blockade of virus attachment, or fusion, or both [9] . In the case of dengue, conventional assays provide an imperfect correlation between neutralizing antibody titre and protection [3, 4, 10] . This might not be surprising as DENVs preferentially replicate in cells of monocyte or macrophage lineage in vivo [11] , and neutralization might be governed by different mechanisms in cells that display antibody Fc-γ receptors (FcγRs) than in those that do not. Moreover, antibodies might paradoxically enhance dengue replication in monocyte or macrophage by FcγR-mediated antibody-dependent enhancement (ADE), a mechanism widely hypothesized to be central to the pathogenesis of DHF [12] .
The current status of dengue vaccine development has been recently summarized [1, 13] , and thus will only be briefly reviewed. Instead, we will focus on reviewing the measurement of dengue neutralizing antibody responses as they relate to antibody FcγR-bearing cells. We will also discuss potentially useful modifications of current neutralization assay methodologies that might offer improved correlation between neutralization activity and protection.
Historical background of dengue vaccine development
Dengue infections, in most cases, manifest as selflimiting undifferentiated febrile illnesses easily confused with those caused by other infectious agents. The possibility of multiple dengue types was suggested by field observations of sequential infections with dengue-like illness [14] . Generally neglected in contemporary discussions concerning dengue vaccine development is the seminal work of Sabin et al. [15, 16] and Dorrance et al. [17] during and shortly after World War II. Their studies with mouse brain-passaged live-attenuated dengue vaccines delivered to volunteers who were then challenged with wild-type virus inform any discussion of protective neutralizing antibodies and their measurement. Together, these studies revealed the following: classical dengue fever developed in volunteers inoculated with serum from patients with acute disease; DENV caused lethal encephalitis in mice (a feature now understood to be generally shared among flaviviruses); and, continuous mouse brain propagation of DENV increased its neurovirulence in mice. At very high passage (at least 15), however, this virus became progressively more attenuated for humans, causing only low-grade fever and trivial rashes. Thus, mouse brain-passaged dengue formed the basis for the first human dengue vaccine [16] .
In these studies, it was estimated that material from the brain and spinal cord of a single mouse was adequate to immunize 10,000 people. Antibodies generated by dengue infection, whether naturally acquired or by vaccination with mouse brain-passaged virus, were found to protect mice against lethal encephalitis when mixed with DENV before intracerebral challenge. Interestingly, it was also shown that human serum neutralizing antibody could be titrated by its capacity to abrogate local erythema and swelling produced by intracutaneous inoculation of volunteers with wild-type DENV, a method that allowed neutralization testing of up to 40 different sera in a single dengue-naive individual. Most importantly, neutralizing activity was demonstrated by failure of dengue fever to develop in volunteers inoculated with mixtures of dengue convalescent serum and wild-type virus. At least two distinct dengue types (DENV-1 and DENV-2) were characterized from Hawaii, New Guinea and India on the basis of failure of cross-neutralization in patients. Nevertheless, these data were gathered from relatively small cohorts.
A large-scale field trial in military personnel was planned, but never carried out as World War II ended. In 1952, the first demonstration of virus plaque formation in tissue culture (Western equine encephalitis virus in chick embryo fibroblasts) was published by Dulbecco [18] . The method proved the feasibility of quantifying virus, and in parallel titrations in eggs demonstrated that a single virus particle might establish infection in vivo. Around the same time, tissue culture methods involving primary and continuous monkey kidney cell lines were developed for poliovirus propagation. Such cells were found suitable for DENV propagation, as well as neutralization testing by PRNT [19] . The simplicity and reproducibility of these assay formats rapidly supplanted the much more cumbersome passive transfer antibody neutralization tests performed in mice. To our knowledge, formal comparisons between the new tissue culture methods and the aforementioned in vivo protective neutralization antibody measurements have not been published.
Current dengue vaccine strategies being evaluated
Dengue vaccine development is hindered by ADE, whereby the presence of inefficiently neutralizing antibodies generated during a primary immune response against dengue enhance infectivity of a second serotype by the formation of infectious immune complexes [14] . In order to circumvent ADE, several vaccines under development aim to elicit tetravalent neutralizing antibody responses. Such vaccine strategies include: liveattenuated vaccines, chimeric vaccines in which the envelope (E) and pre-membrane (prM) gene sequence of yellow fever vaccine strain (YF17D) has been replaced by that of a different flavivirus, 3′ untranslated region (3′UTR) deletion mutants, DNA vaccines, recombinant subunit vaccines and purified formalin-inactivated virus. The status of development of these dengue vaccines has been recently summarized [1, 13] , and thus only clinical trial experience and selected non-human primate studies will be reviewed.
Live-attenuated vaccines
Live-attenuated viruses against all four dengue serotypes have been developed at both Mahidol University (Bangkok, Thailand) and the Walter Reed Army Institute of Research (WRAIR; Washington, DC, USA). DENV attenuation was achieved through serial passage in primary dog kidney (PDK) cells or African green monkey kidney cells (AGMK ; Table 1 ) [20, 21] .
In a Phase I clinical trial, monovalent DENV vaccine formulations developed at WRAIR induced neutralizing antibody responses, as measured by the traditional PRNT, following administration of a single dose: 100% to DENV-1 (strain 45AZ5), 67% to DENV-2 (strain S16803), 50% to DENV-3 (strain CH53489) and 63% to DENV-4 (strain 341750) [22] . Candidate tetravalent vaccines were further evaluated in a Phase I clinical trial, and the resulting 38% seroconversion rate against DENV-4 component was lower than those against the other serotypes: DENV-1 (69%), DENV-2 (78%), DENV-3 (69%) [23] , thus revealing an unbalanced response against the four serotypes. A Phase II clinical trial using a lower PDK passage of the DENV-4 component virus, and higher PDK passage of the DENV-1 component virus demonstrated 63% seroconversion to all four dengue serotypes following two doses administered 6 months apart [24] .
In initial studies at Mahidol University, various vaccine preparations of DENV-1, -2, -3 and -4 were used either alone or in combination. A Phase I trial showed 100% seroconversion against DENV-2, DENV-3 and DENV-4, as well as 60% seroconversion against DENV-1 following administration of a single dose of monovalent vaccines. After receiving a single dose of tetravalent vaccine, 10/10 (100%) adult volunteers experienced seroconversion to DENV-3, but only 70% to DENV-1, and even fewer to DENV-2 (20%) and DENV-4 (10%) [25] . In a follow-up trial of 43 participants, two vaccine doses given 6 months apart increased seroconversion rates to 76% against three dengue serotypes and 71% against all four [26] . Decreasing the DENV-3 component in the tetravalent vaccine, as well as administration of a second dose, partially overcame the immune dominance of the DENV-3 vaccine component [27] . However, trials of Mahidol tetravalent dengue vaccine were stopped after an attempt to further attenuate the DENV-3 component failed when tested in susceptible adults in Hong Kong.
Chimeric vaccines
Because YF17D is a licensed yellow fever vaccine, and yellow fever and DENV are structurally similar, developing a chimeric dengue vaccine using YF17D as a backbone offers a promising strategy. These chimeric dengue vaccines (ChimeriVax™-DEN; Acambis, Cambridge, MA, USA) are made by replacing YF17D prM/E genes that contain neutralization epitopes with the homologous regions from each of the four dengue serotypes. These vaccines have been tested either individually or in combination. In a Phase I trial of ChimeriVax™-DEN2 in yellow fever (YF)-naive volunteers, 100% and 92.3% achieved seroconversion following administration of either a high dose (5 log 10 plaque-forming units [PFU]) or a low dose (3 log 10 PFU) of vaccine virus, respectively. The same vaccine evaluated in YF-immune volunteers elicited 100% seroconversion against all four dengue serotypes following a single dose, and neutralizing antibodies against DENV-1, DENV-2 and DENV-3, but not DENV-4. These anti-dengue antibodies persisted for 1 year following the initial immunization, thus demonstrating that pre-existing immunity against YF does not interfere with ChimeriVax™-DEN2 vaccine immunogenicity [28] . In addition to not interfering with DENV-2 antibody response, YF priming actually increases the DENV-2 titre and widens the response to other DENV serotypes. It is unclear if such heterologous antibody will predispose to DHF after subsequent infection by one of these heterologous serotypes. One vaccine company, Sanofi Pasteur, plans to begin in 2009 a Phase IIb/ III clinical trial in Thai children using a combination of all four chimeric dengue vaccines (ChimeriVax™-DEN1 to DEN4).
3′UTR deletion mutant vaccines
The US National Institutes of Health (NIH) has developed vaccine candidates against all four dengue serotypes by attenuating these viruses with a deletion of a 30-nucleotide sequence (∆30) in the 3′UTR. Chimeric viruses utilizing rDEN4∆30 as a backbone were generated by replacing prM/E genes with those of either DENV-1, DENV-2 or DENV-3. Preclinical evaluations in rhesus monkeys identified a number of candidate vaccines: rDEN1∆30, rDEN2∆30, rDEN4∆30, rDEN1/4∆30, rDEN2/4∆30 and rDEN2/4∆30 [29] [30] [31] [32] .
In Phase I clinical trials, there was 95-100% seroconversion following administration of a single dose of either rDEN1∆30, rDEN2/4∆30 or rDEN4∆30 [33] [34] [35] . Additionally, these vaccines were found to be safe and well tolerated. Table 2 provides additional virological and immunological information on these vaccine constructs.
Alternative approaches
Although the above-described dengue vaccine candidates are being evaluated in various phases of human clinical trials, candidate vaccines employing alternative strategies are being developed. The US Navy Medical Research Center (Washington, DC, USA) has developed a DNA vaccine encoding the prM/E of DENV-1 [36] . A second approach, being pursued by Hawaii Biotech, involves the administration of recombinant subunit vaccines composed of 80% of the E glycoprotein amino terminus from all four dengue serotypes, formulated in combination with DENV-2 non-structural protein 1 as recombinant proteins [37] . A third approach, that of a purified formalin-inactivated virus, has been developed by WRAIR against DENV-2 [37] . All these approaches are currently in the preclinical stages of development.
Selected examples of preclinical dengue vaccine studies in rhesus macaques
A major obstacle to dengue vaccine development is the lack of an ideal animal model of human dengue disease. Although non-human primates are susceptible to dengue infection, they do not typically develop clinical signs of disease such as fever, petechiae, haemorrhage or shock. Despite this limitation, monkeys remain the mainstay of immediate preclinical evaluation of dengue vaccines because of their close genetic proximity to humans, and the possibility of challenging them with wild-type DENV post-vaccination in order to test the ability of the vaccine to inhibit viraemia. The majority of such research is carried out in Old World monkeys (Macaca mulatta), although some dengue vaccines have also been evaluated in both New World (Aotus nancymae) and other Old World monkeys (Macaca cynomolgus) species (Table 2) . These vaccine trials in non-human primates have some limitations; candidate vaccines are derived from a wide range of viral strains, and the testing of vaccine immunogenicity and efficacy are not standardized. The immunogenicity results are difficult to interpret because the cells used to measure Vero neutralization antibody titre vary, the viral strains used to test antibody neutralization differ, the PRNT end point titres for determining efficacy are not uniform, and challenge viruses are mostly autologous to the vaccine strain. These experimental inconsistencies confound attempts to draw absolute correlations between neutralizing antibody titre (seropositivity) and protection from viraemia upon experimental viral challenge or natural infection. Indeed, several dengue vaccine candidates that elicited between 13-100% seroconversion in non-human primates were unable to prevent viraemia following dengue viral challenge ( Table 2) .
Even a theoretical measure of neutralization, such as the relative levels of PRNT titres as determined by routinely used assays, do not consistently predict protection. For example, vaccination with a tetravalent liveattenuated dengue vaccine in rhesus monkeys induced an 80% seroconversion against DENV-4, and 100% seroconversion against DENV-1, -2 and -3. When seropositive animals were subsequently challenged with heterotypic viruses, approximately 20% of the animals experienced viraemia against DENV-1, -3 and -4, but all were protected against DENV-2 (Table 2) [4] . Moreover, in the DENV-3 challenge group, all animals were considered seropositive (PRNT 50 ≥10), but an animal with a pre-challenge low titre of 1:13 was protected against challenge, whereas another with a high titre of 1:119 was viraemic for 6 days [4] .
In order to make the PRNT a better predictor of protection against challenge, two improvements are desirable: one is the identification of a protective end point PRNT titre, another is the selection of cell type different from the one used in the present conventional assays.
In vitro testing for dengue vaccine efficacy
In order to prepare for large-scale dengue vaccine Phase III clinical trials that involve multiple clinical sites and many laboratories, it is highly desirable that standardized assays are used to assess immunogenicity and vaccine efficacy. Because all dengue vaccines currently under development aim to elicit a protective antibody response, a robust neutralization assay needs to be established. According to a World Health Organization committee's recommendations [6] , such an assay should have high sensitivity and specificity, high reproducibility, easy transferability and high-throughput performance.
PRNT titre is routinely used to measure dengue neutralizing antibody response [19, 38] . The potency of a neutralizing antibody is presented as reciprocal antibody dilutions at which 50-90% (PRNT 50 or PRNT 90 ) of viral infectivity is neutralized. PRNT 50 value was initially considered a good benchmark for antibody potency [19] . Over the ensuing years, variations of this basic assay design emerged to include the use of multiple cell types, and different PRNT end point titres were thought likely to be biologically significant, largely based on intuitive assumptions. Despite the technical variability, this fundamental assay design has been widely used in studies of dengue pathogenesis and virtually all clinical trials of candidate dengue vaccines.
A consideration unique to the development of an assay for assessment of the anti-dengue antibody responses is the influence of FcγRs on antibody-mediated neutralization and enhancement of DENV replication [14, 39, 40] . Contemporary neutralization tests in FcγR-negative cells, such as Vero (AGMK epithelial cell) and LLC-MK2 (rhesus monkey kidney epithelial cell), are accurate in demonstrating monotypic immunity and predicting protection against homotypic DENV challenge, but they are unable to predict protection against secondary heterotypic dengue infections. By contrast, modified neutralization assays using CV-1 cells (AGMK fibroblasts) engineered to express FcγRIIa were shown to have improved correlation between PRNT titre and protection [41, 42] . More importantly, when children's pre-secondary infection sera were tested undiluted in human monocytes that express FcγR, the results correctly predicted which children had unapparent infections (those with DENV-2 neutralizing antibodies) and those who were hospitalized (those with DENV-2 enhancing antibodies) [43] . The influence of specific cell types is an underappreciated factor in DENV neutralizing antibody measurement, and thus will be further discussed.
Neutralization and enhancement assays used in laboratory research
ADE is a major consideration and possible impediment in dengue vaccine development [1, 44] . It is evident in principle that ADE is best measured in physiologically relevant cells that express FcγR on their surface, that is, primary human monocytes and macrophages. However, to circumvent the logistic complexity and biological variability inherent to ADE measurement in such cells, many investigators have opted to use established cell lines for experimental dengue research. Cell lines, either expressing FcγR or not, are easy to maintain and manipulate in cultures, intraassay variations are usually reasonably small, and their supply is assured. But results obtained using cell lines might not necessarily be biologically relevant.
Among cell lines employed to study dengue neutralization and enhancement, these are human FcγR expressing cell lines, such as K562 (erythroleukaemia cell), U937 (histocytic lymphoma cell), THP1 (monocytoid leukaemia cell), as well as non-human cell lines that either express FcγR, like P388 D1 (murine macrophage) or not, such as Vero, LLC-MK2, CV-1 and BHK21 (baby hamster kidney fibroblast). It is important to note that these cells have fundamental genetic differences (Tables 3 and 4) [19, [45] [46] [47] [48] , and these differences could influence the capacity of a particular antibody to neutralize the same virus in a different cell type. For instance, BHK21 and LLC-MK2 cells exhibit a good agreement in PRNT titres for all four serotypes of DENVs with the same anti-dengue antibodies [49] . But how they compare with PRNT performed in Vero or CV-1 cells has not been examined.
K562, U937 and THP1 cell lines have all been used to measure immune enhancement of DENV infectivity. How they compare with each other, or perhaps more crucially, with primary human monocytes, has not been investigated. Other than the divergence in FcγR expression among these cell lines (Table 3) , their relative permissiveness to dengue viral infection in the absence of enhancing antibodies is markedly different. K562 cells are easy to infect, whereas U937 and THP1 cells are difficult to infect in the absence of enhancing antibodies. Antibody-mediated enhancement of infectivity is readily demonstrated in K562 cells with a low input dengue viral multiplicity of infection (MOI) of 0.1, but requires a much higher MOI (1-10) for U937 and THP1 cells [48, [50] [51] [52] . In this respect, U937 and THP1 are similar to primary human monocytes that require a high MOI to demonstrate ADE [53] . Another difference worth noting is that U937 cells express low levels of FcγRIA (CD64) and high levels of FcγRIIA (CD32), whereas THP1 cells express intermediate levels of FcγRIA (CD64) and high levels of FcγRIIA (CD32), and K562 cells only express FcγRIIA (CD32) [50, 54] . How each of the FcγR affects ADE infection in these cell lines has not been systematically examined.
Neutralization and enhancement assays used in dengue vaccine clinical trials
Despite the lack of uniformity among existing neutralization and enhancement assays, some have been applied to the assessment of human antibody responses induced by candidate dengue vaccines. In a Phase I clinical trial of a live-attenuated tetravalent dengue vaccine, robust neutralization activity was demonstrated by PRNT performed in LLC-MK2 cells [55] . In human clinical trials of monovalent live-attenuated recombinant DENV-1 and DENV-4 vaccines, Vero cells were used to measure antibody PRNT titres [34, 35] . However, there has not been a formal comparison between neutralization antibody titres when LLC-MK2 and Vero cells are tested with the identical input virus and antiserum.
Although not yet included as a primary end point for human clinical trials, an attempt has also been made to measure the induction of dengue enhancing antibodies in K562 cells by a flow cytometric (FACS) method. Using this assay, no dengue-enhancing activity was detected in the sera of tetravalent dengue vaccine recipients [56] .
Shortcomings of current dengue neutralization and enhancement assays
A major concern regarding the traditional PRNT is that it is performed in Vero or LLC-MK2 cells that do not express FcγR, which are expressed abundantly in the principal human dengue target cells: monocytes, macrophages and myeloid dendritic cells that are capable of mediating increased dengue infectivity through immune complex infection [43, 53, 57, 58] . In addition, the key, but generally unappreciated fact that these cells do not produce antiviral interferon (IFN)-α and -β as do monocyte or macrophages and dendritic cells is another source of concern. We posit that this feature must be considered in choosing cell type surrogates of primary monocyte or macrophages for neutralization and ADE measurements. Neutralization assays performed with the same DENV and same dengue-immune sera were found to have significantly different PRNT titres in two monkey fibroblast cell lines, Vero (lacking IFN-α and -β) and CV-1 (having IFN-α and -β; Table 4 ) [42] . Moreover, IFN-α and -β are known to inhibit dengue viral replication in cell cultures in vitro [59, 60] , as well as in murine models in vivo [61, 62] .
With these considerations in mind, we conjecture that K562 cells might be the least physiological cell type for ADE assays because they lack the entire gene locus that encodes multiple type-I IFN genes [63] . Vero cells are similarly deficient because they are devoid of an IFN-β gene [64] . The selection of an appropriate cell type for neutralization and enhancement assay is not merely an academic exercise, different choices of cell types can sometimes result in opposite interpretations of the same biological event [65] [66] [67] .
New neutralization and enhancement assays under development
To overcome the drawbacks of time-consuming, labour intensive, and low throughput of the traditional PRNT that uses vital dye staining for visualization of viral plaques, a number of new assays have been developed. One is a microneutralization assay, which utilizes ELISA methods to quantify the amount of viral antigens in the infected cell lysate instead of counting plaques [68] .
Another quantifies the proportion of infected cells using the FACS analysis, which has already been applied to C6/36 mosquito cells and Raji B cell lines engineered to express a dengue viral entry receptor: dendritic cellspecific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) [69] [70] [71] . These new methods have reduced assay time from 5-7 days required for the traditional PRNT to 24-48 h, increased the sensitivity of detection, and improved assay throughput [72] . However, results obtained from each of these assays are not always comparable. When PRNT and microneutralization assay were compared in Vero cells, a good general correlation was found between the two methods only for sera obtained from primary dengue infections, but not for sera obtained from secondary infections [68, 72] . In another study employing a FACS-based assay in Raji-DC-SIGN cells, there was poor agreement with results from traditional PRNT or a micro neutralization assay [72] . To complicate the issue further, the 50% maximal inhibitory concentration (IC 50 ) values obtained from PRNT performed in Vero cells were almost identical to those derived from a FACS-based neutralization assay in Raji-DC-SIGN cells, but the IC 90 values differed by five-to sixfold between these two neutralization assays [71] .
In an attempt to improve the current neutralization assays, we have modified CV-1 cells, a cell type that has been used for conventional dengue PRNT, to express various FcγRs (Table 3 ). These cells secrete type-I IFNs upon in vitro dengue viral infection (XJ, unpublished observation), and they can be used to measure both neutralization and enhancement of viral infectivity [73] . Moreover, an assay with CV-1-FcγR cell lines can be readily developed into a high-throughput format [42] . These findings suggest that CV-1-FcγR cell lines offer a novel way to gauge neutralization and ADE simultaneously in a manner superior to existing assays. Validation of such an assay, of course, requires demonstration of its comparability to primary human monocytes, and more importantly its correlation with dengue disease severity as well as its ability to predict dengue vaccine efficacy. It would also be informative to compare CV-1-FcγR cell lines with Vero and LLC-MK2 cells in addition to human monocytes. These validations might be possible with sera from well characterized cohorts comprising dengue-infected patients or recipients of candidate dengue vaccines.
Summary
Various candidate dengue vaccines being tested in clinical trials have unique properties. An ideal DENV vaccine formulation must be tetravalent, safe, immunogenic and able to provide durable immunity against all four dengue serotypes. However, an overarching question remains: How do we accurately measure a protective neutralizing antibody response induced by vaccination? Testing neutralizing antibody response in the context of dengue infection and vaccination has mostly been performed in vitro in cell lines, either expressing FcγR or not, chosen largely on the basis of permissiveness to plaque formation, and sometimes in vivo in experimentally DENV-challenged monkeys. None of the in vitro assays are ideal, and the in vivo monkey assays are expensive to perform. A possible solution is the introduction by genetic engineering of human FcγRs in cells used in a conventional DENV neutralization assay, which might provide a relatively simple and more accurate means to obtain neutralization results that correlate more closely with protection conferred by either natural infection or vaccination [71] .
